Geoffrey L. Greene, Ph.D.


Le TP, Sun M, Luo X, Kraus WL, Greene GL. Mapping ERbeta Genomic Binding Sites Reveals Unique Genomic Features and Identifies EBF1 as an ERbeta Interactor. PloS one. 2013;8(8):e71355.

Huang W, Greene GL, Ravikumar KM, Yang S. Cross-talk between the ligand- and DNA-binding domains of estrogen receptor. Proteins. 2013.

Chapa J, Bourgo RJ, Greene GL, Kulkarni S, An G. Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics. PloS one. 2013;8(5):e64091.

Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast cancer research and treatment. 2013;137(2):373-382.

Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Young Park S, Eileen Dolan M, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nature communications. 2013;4:1393.

Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife. 2013;2:e00499.

Romero IL, Lee W, Mitra AK, Gordon IO, Zhao Y, Leonhardt P et al (2012). The effects of 17beta-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol 124: 134-141.

Walker MP, Zhang M, Le TP, Wu P, Laine M, Greene GL (2011). RAC3 is a pro-migratory co-activator of ERalpha. Oncogene 30: 1984-1994.

Liu H, Bockhorn J, Dalton R, Chang YF, Qian D, Zitzow LA et al (2011). Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sorting. Journal of virological methods 173: 266-270.

Sinkevicius KW, Woloszyn K, Laine M, Jackson KS, Greene GL, Woodruff TK et al (2009). Characterization of the ovarian and reproductive abnormalities in prepubertal and adult estrogen non-responsive estrogen receptor alpha knock-in (ENERKI) mice. Steroids 74: 913-919.

Sinkevicius KW, Laine M, Lotan TL, Woloszyn K, Richburg JH, Greene GL 2009 Estrogen-dependent and -independent estrogen receptor-alpha signaling separately regulate male fertility. Endocrinology 150:2898-2905

Sinkevicius KW, Burdette JE, Woloszyn K, Hewitt SC, Hamilton K, Sugg SL, Temple KA, Wondisford FE, Korach KS, Woodruff TK, Greene GL 2008 An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology 149:2970-2979

O'Neill EE, Blewett AR, Loria PM, Greene GL 2008 Modulation of alphaCaMKII signaling by rapid ERalpha action. Brain Res 1222:1-17

Nettles KW, Gil G, Nowak J, Metivier R, Sharma VB, Greene GL 2008 CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. Mol Endocrinol 22:263-272

Nettles KW, Bruning JB, Gil G, Nowak J, Sharma SK, Hahm JB, Kulp K, Hochberg RB, Zhou H, Katzenellenbogen JA, Katzenellenbogen BS, Kim Y, Joachmiak A, Greene GL 2008 NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol 4:241-247

Leong H, Mathur PS, Greene GL 2008 Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res Treat

Leong H, Mathur PS, Greene GL 2008 Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Res Treat 107:359-369

Hsieh RW, Rajan SS, Sharma SK, Greene GL 2008 Molecular characterization of a B-ring unsaturated estrogen: Implications for conjugated equine estrogen components of Premarin. Steroids 73:59-68

Nettles KW, Bruning JB, Gil G, O'Neill EE, Nowak J, Guo Y, Kim Y, DeSombre ER, Dilis R, Hanson RN, Joachimiak A, Greene GL 2007 Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO Rep 8:563-568